Monitor for interim safety and efficacy signals from the Phase 1b trial in 2027; upcoming mid-2026 update on future combination plans may provide additional catalysts. No immediate revenue potential, but successful data could enhance partnership or licensing prospects.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 25 $2.69entry
- T+1 · 8mo ago −2.60%α −0.83% · $2.62
- T+5 · 8mo ago +0.37%α +0.62% · $2.70
- T+20 · 7mo ago +10.41%α +2.55% · $2.97
- T+60 · 5mo ago +52.60%α +39.15% · $4.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
C4 Therapeutics has dosed the first patient in a Phase 1b trial combining its investigational drug cemsidomide with Pfizer's FDA-approved elranatamab for relapsed/refractory multiple myeloma. The trial aims to evaluate safety and preliminary efficacy, with data expected in mid-2027, representing a strategic step in advancing cemsidomide across multiple treatment lines.
Key Facts
- First patient dosed in a Phase 1b trial combining cemsidomide with elranatamab (ELREXFIO®) for relapsed/refractory multiple myeloma (RRMM).
- Trial will evaluate cemsidomide at 50 µg, 75 µg, and 100 µg doses in combination with elranatamab; up to 54 patients to be enrolled.
- Primary endpoint is safety and tolerability; secondary endpoints include overall response rate, MRD-negative complete response, and duration of response.
- Pfizer is providing elranatamab at no cost under a clinical trial collaboration agreement; C4T is sponsoring and conducting the trial.
- Phase 1b data anticipated in mid-2027; part of a broader strategy that includes the ongoing Phase 2 MOMENTUM trial.
Financial Impact
No direct financial impact disclosed; trial costs expected to be partially offset by Pfizer's drug supply.
Risk Factors
- Clinical development risk: Combination therapy may show unacceptable toxicity or lack of efficacy.
- Dilution risk: C4T may need to raise capital to fund ongoing trials, potentially diluting shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262063 |
Track record
19 reports on CCCC
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers